Microbiome startup Kaleido Biosciences has closed its oversubscribed Series C financing round at $101m. Investment came from Fidelity Management, Invus, as well as a subsidiary of Abu Dhabi Investment Company and Flagship Pioneering, Kaleido’s founder.

The company total’s capital since it was founded in 2015 equals approximately $165m. This investment will be used to advance Kaleido’s microbiome metabolic therapies pipeline, which aims to create and develop a microbiome therapeutic strategy that adds or subtracts bacteria with the goal of influencing microbes that make up the gut microbiome. It has focused on rare genetic diseases, as well as oncology and metabolic diseases.

Kaleido chief executive and office and chair Michael Bonney said: “We are pleased to have support from our new and existing investors who share Kaleido’s excitement in leveraging the therapeutic potential of the microbiome and the promise of accelerating the discovery and development of products for patients.

“With our differentiated approach, we have an opportunity to lead a revolution in health and deliver novel treatments for a range of diseases and conditions.”

Kaleido claims its research and developmen approach is novel and helps to advance therapeutic candidates in the clinic quickly and cheaply, as well as enabling early and continuous integration of human data and better translatability between ex vivo and in vivo.

The company currently has four programmes in early stage clinical trials, including two Phase II trials in hyperammonemia, which is a metabolic issue characterised by excessive ammonia in the blood.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Flagship founder and chief executive officer Noubar Afeyan said: “We believe Kaleido has the potential to break the mould of traditional therapeutic product development. In just three years Kaleido has conducted ten human clinical studies, produced a robust pipeline and assembled a world-class leadership team.”